Danish Vulva Cancer Recurrence Study
Key facts
- Who runs it
- University of Aarhus
- Where
- Denmark2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,295 people, planned
- Started
- 15 Aug 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Measurement of circulating tumor-DNA
- Collection of patient-reported outcomes
- Algorithmically determined telephone interview with a nurse
- Record updated
- 29 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Primary or recurrent biopsy-verified squamous cell carcinoma of the vulva
- ≥ 18 years of age
- Able to understand oral and written information in Danish
Who cannot take part
- Active treatment for concurrent cancer and/or dissemination of concurrent cancer
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.
Read full original descriptionShow less
DaVulvaRec is a Danish nationwide multicenter study with patient inclusion from Aarhus University Hospital and Rigshospitalet, Denmark. Applying a mixed method research design, the investigators will collect and analyze patient-reported outcome measures in combination with procedural data to evaluate symptomatology and map actions taken during the patient's pathway from primary disease to recurrence. Furthermore, the investigators aim to examine if circulating tumor-DNA (ctDNA) can be detected in liquid biopsies from VC patients. All patients will be followed for two years or until recurrence. Patient-reported outcome measures will be completed every four months during surveillance, and liquid biopsies will be collected prospectively for later analyses.
Total number of patients to be included is 295 according to a power calculation. All patients in the clinical study will be included in the intervention group, while data on a historical control group will be obtained from The Danish Gynecological Cancer Database. Hence, the control group will consist of 1000 VC patients diagnosed between 2011-2022.
Hypotheses:
* All patients with VC will have specific tumor markers in the primary tumor that will be detectable in liquid biopsies as ctDNA at the time of diagnosis. * Measurement of ctDNA after primary treatment and during surveillance will allow detection of residual disease, improve allocation for adjuvant treatment, and will allow early detection of recurrent VC. * Proactive use of repeated PROM assessments in combination with procedural actions during surveillance will allow early detection of recurrent VC and early identification of late effects after treatment.
The 2 groups in the trial
- PROM assessment and ctDNA detection during surveillanceTreatment being tested
All participants (n=295) included in the prospective clinical study
Treatment: Measurement of circulating tumor-DNA, Collection of patient-reported outcomes, and Algorithmically determined telephone interview with a nurse
- Standard surveillanceNo study treatment, for comparison
Historical controls (n=1,000) who will be identified by the Danish Gynecological Cancer Database
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Value of Patient-reported Outcome Measure Assessment and Circulating Tumor-DNA to Detect Early Relapse During Surveillance in Women With Vulva Cancer
- Record updated
- 29 April 2026